Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment exchanges : Nasdaq save search
Genentech’s ALK Inhibitor First Adjuvant Treatment for ALK-Positive, Early NSCLC
Published: 2024-04-19 (Crawled : 15:00) - biospace.com/
PRGO | News | $30.8 2.87% -1.14% 1.2M
|
Health Technology
|
| O: -0.4%
H: 3.01%
C: 2.94%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.83%
H: 1.35%
C: 1.2%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.39%
H: 1.69%
C: 1.23%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.83%
H: 1.83%
C: 0.89%
first treatment for
Progressive Familial Intrahepatic Cholestasis Treatment Market Projected to Reach $156.14 million by 2030 - Exclusive Report by 360iResearch
Published: 2024-04-19 (Crawled : 02:00) - prnewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.23%
H: 0.61%
C: 0.46%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.83%
H: 1.83%
C: 0.89%
MIRM | News | $23.83 1.1% 1.09% 340K
|
Health Technology
|
| O: -0.68%
H: 2.52%
C: 1.71%
report million reach treatment market
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
MBRX | $4.65 2.8% 2.72% 11K
|
Health Technology
|
| O: 4.91%
H: 11.36%
C: 0.67%
drug treatment designation for grants leukemia
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Published: 2024-04-18 (Crawled : 13:00) - globenewswire.com
ONCT | $8.97 4.3% 4.12% 4.5K
|
Health Technology
| Email alert
Add to watchlist
onct-534 first cancer treatment for study
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
Published: 2024-04-17 (Crawled : 22:00) - biospace.com/
DMAC | $2.46 -1.21% -1.22% 21K
|
Health Technology
|
| O: 4.43%
H: 0.0%
C: 0.0%
dm199 first stroke treatment for trial therapeutics
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
Published: 2024-04-17 (Crawled : 13:00) - globenewswire.com
ABVC | $0.9899 -5.72% -6.07% 160K
|
Wholesale Trade
|
| O: 2.68%
H: 3.48%
C: -11.3%
treatment biopharma royalties global for agreement
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
Published: 2024-04-17 (Crawled : 12:00) - prnewswire.com
NRBO | $3.325 -3.34% -3.46% 21K
|
Health Technology
|
| O: 8.53%
H: 0.0%
C: -6.23%
da-1726 obesity first treatment pharmaceuticals for trial
New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
GENE 1 d | $2.27 -6.97% -7.49% 64K
|
Health Technology
|
| O: 3.47%
H: 0.0%
C: -3.66%
precision treatment
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
CMND | $1.22 3.56% 3.43% 110K
|
n/a
|
| O: -0.82%
H: 0.0%
C: 0.0%
disorders treatment for agreement
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
SAGE | $13.35 2.42% 2.36% 1.3M
|
Health Technology
|
| O: -15.02%
H: 3.55%
C: -3.01%
sage-718 disease treatment topline parkinson’s therapeutics results study
Prostate Cancer: Advancements in Prevention and Treatment Drive Global Market Growth
Published: 2024-04-17 (Crawled : 09:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.12%
H: 0.51%
C: 0.51%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.04%
H: 0.28%
C: -0.16%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
treatment global growth market
Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
Published: 2024-04-16 (Crawled : 20:00) - globenewswire.com
CLNN S | $0.3492 5.85% 5.53% 1.2M
|
| Email alert
Add to watchlist
au8 neurology sclerosis treatment for meeting
Sentynl Therapeutics Receives MHRA Authorization of NULIBRY® (fosdenopterin) for Treatment of MoCD Type A in Great Britain
Published: 2024-04-16 (Crawled : 16:00) - biospace.com/
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: -1.47%
H: 2.05%
C: -0.59%
nulibry authorization treatment for therapeutics
Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market Research
Published: 2024-04-16 (Crawled : 14:00) - prnewswire.com
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.53%
H: 0.0%
C: -1.24%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -1.46%
H: 0.0%
C: 0.0%
PHG | $19.98 0.0% 540K
|
Health Technology
|
| O: -1.21%
H: 0.0%
C: 0.0%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -1.19%
H: 0.52%
C: -0.17%
VRNA | $15.82 -1.74% -1.83% 640K
|
Health Technology
|
| O: 1.65%
H: 2.43%
C: 0.87%
reach treatment research market
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
Published: 2024-04-16 (Crawled : 12:00) - globenewswire.com
LXEO | $11.995 -0.62% -0.63% 87K
|
|
| O: 5.32%
H: 0.0%
C: -2.63%
lx2006 fda candidate granted treatment designation for therapeutics therapy
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
Published: 2024-04-15 (Crawled : 21:00) - globenewswire.com
ZVRA | $4.515 0.33% 0.33% 360K
|
n/a
|
| O: 1.15%
H: 1.03%
C: -1.45%
disease treatment for meeting therapeutics
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea & Vomiting at the Upcoming ASPAN 2024 National Conference in Orlando, Florida
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
EGRX | $4.63 3.35% 3.24% 60K
|
Health Technology
|
| O: -8.14%
H: 19.55%
C: 18.18%
conference treatment pharmaceuticals for trial response
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
RARE | News F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: -10.79%
H: 0.0%
C: -3.75%
gtx-102 positive treatment
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
EGRX | $4.63 3.35% 3.24% 60K
|
Health Technology
|
| O: -8.14%
H: 19.55%
C: 18.18%
conference treatment pharmaceuticals for trial response
Euro Tech Holdings Company Limited Reported An Exclusive Sales Distribution And OEM Partnership Agreement Covering Ballast Water Treatment Systems ("BWTS") Has Been Signed Between PACT And ERMA FIRST
Published: 2024-04-15 (Crawled : 11:00) - prnewswire.com
CLWT | $1.54 0.0% 1.5K
|
Electronic Technology
|
| O: 1.1%
H: 0.19%
C: 0.19%
sales water partnership first company distribution treatment agreement
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.